What Is New in the Management of Skin and Soft Tissue Infections in 2016?

Garyphallia Poulakou; Efthymia Giannitsioti; Sotirios Tsiodras


Curr Opin Infect Dis. 2017;30(2):158-171. 

In This Article


ABSSSIs are one of the most common causes of ambulatory visits and represent a substantial percentage of admissions in medical and – to a lesser extent – in surgical wards. Despite the availability of many antimicrobials with antistaphylococcal activity including some newly launched antibiotics, S. aureus remains the cardinal pathogen in ABSSSIs; treatment challenges derive mainly because of the expansion of MRSA (including both CA-MRSA and Hospital-acquired MRSA). Many recent studies focus on early recognition of risk factors for relapse or failure of treatment and early assessment of clinical response to guide de-escalation and early hospital discharge. Current literature indicates that properly constructed algorithms should be adopted in the EDs, to select the correct patient for outpatient treatment and recognize early those with risk factors for nonresponse. In this context, except for disease severity and extent, nonpharmacologic parameters such as comorbidities should be taken into account. The addition of new long-acting antibacterials in the current armamentarium offers new possibilities for outpatient management of ABSSSIs and healthcare cost reduction. Prospective studies are important to clearly delineate the use of new antibiotics with anti-MRSA activity in future practice. Novel approaches such as phage therapy are promising and may completely change the therapeutic field of SSTIs in the future.